Deficient natural killer cell cytotoxicity in patients with IKK-γ/NEMO mutations

Jordan S. Orange, Scott R. Brodeur, Ashish Jain, Francisco A. Bonilla, Lynda C. Schneider, Roberto Kretschmer, Samuel Nurko, Wendy L. Rasmussen, Julia R. Köhler, Stephen E. Gellis, Betsy Ferguson, Jack L. Strominger, Jonathan (Jon) Zonana, Narayanaswamy Ramesh, Zuhair K. Ballas, Raif S. Geha

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

NF-κB essential modifier (NEMO), also known as IKK-κ, is a member of the I-γB kinase complex responsible for phosphorylating I-κB, allowing the release and activation of NF-κB. Boys with an expressed NEMO mutation have an X-linked syndrome characterized by hypohidrotic ectodermal dysplasia with immune deficiency (HED-ID). The immunophenotype resulting from NEMO mutation is highly variable, with deficits in both T and B cell responses. We evaluated three patients with NEMO mutations (L153R, Q403X, and C417R) and HED-ID who had evidence of defective CD40 signaling. All three patients had normal percentages of peripheral blood NK cells, but impaired NK cell cytotoxic activity. This was not due to a generalized defect in cytotoxicity because antibody-dependent cellular cytotoxicity was intact. This abnormality was partially reversed by in vitro addition of IL-2, which was also able to induce NF-κB activation. In one patient with recurrent cytomegalovirus infections, administration of IL-2 partially corrected the NK cell killing deficit. These data suggest that NEMO participates in signaling pathways leading to NK cell cytotoxicity and that IL-2 can activate NF-κB and partially overcome the NK cell defect in patients with NEMO mutations.

Original languageEnglish (US)
Pages (from-to)1501-1509
Number of pages9
JournalJournal of Clinical Investigation
Volume109
Issue number11
DOIs
StatePublished - 2002

Fingerprint

Natural Killer Cells
Mutation
Interleukin-2
Cytomegalovirus Infections
Blood Cells
B-Lymphocytes
Phosphotransferases
T-Lymphocytes
Antibodies
Ectodermal dysplasia, hypohidrotic, with immune deficiency

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Orange, J. S., Brodeur, S. R., Jain, A., Bonilla, F. A., Schneider, L. C., Kretschmer, R., ... Geha, R. S. (2002). Deficient natural killer cell cytotoxicity in patients with IKK-γ/NEMO mutations. Journal of Clinical Investigation, 109(11), 1501-1509. https://doi.org/10.1172/JCI200214858

Deficient natural killer cell cytotoxicity in patients with IKK-γ/NEMO mutations. / Orange, Jordan S.; Brodeur, Scott R.; Jain, Ashish; Bonilla, Francisco A.; Schneider, Lynda C.; Kretschmer, Roberto; Nurko, Samuel; Rasmussen, Wendy L.; Köhler, Julia R.; Gellis, Stephen E.; Ferguson, Betsy; Strominger, Jack L.; Zonana, Jonathan (Jon); Ramesh, Narayanaswamy; Ballas, Zuhair K.; Geha, Raif S.

In: Journal of Clinical Investigation, Vol. 109, No. 11, 2002, p. 1501-1509.

Research output: Contribution to journalArticle

Orange, JS, Brodeur, SR, Jain, A, Bonilla, FA, Schneider, LC, Kretschmer, R, Nurko, S, Rasmussen, WL, Köhler, JR, Gellis, SE, Ferguson, B, Strominger, JL, Zonana, JJ, Ramesh, N, Ballas, ZK & Geha, RS 2002, 'Deficient natural killer cell cytotoxicity in patients with IKK-γ/NEMO mutations', Journal of Clinical Investigation, vol. 109, no. 11, pp. 1501-1509. https://doi.org/10.1172/JCI200214858
Orange JS, Brodeur SR, Jain A, Bonilla FA, Schneider LC, Kretschmer R et al. Deficient natural killer cell cytotoxicity in patients with IKK-γ/NEMO mutations. Journal of Clinical Investigation. 2002;109(11):1501-1509. https://doi.org/10.1172/JCI200214858
Orange, Jordan S. ; Brodeur, Scott R. ; Jain, Ashish ; Bonilla, Francisco A. ; Schneider, Lynda C. ; Kretschmer, Roberto ; Nurko, Samuel ; Rasmussen, Wendy L. ; Köhler, Julia R. ; Gellis, Stephen E. ; Ferguson, Betsy ; Strominger, Jack L. ; Zonana, Jonathan (Jon) ; Ramesh, Narayanaswamy ; Ballas, Zuhair K. ; Geha, Raif S. / Deficient natural killer cell cytotoxicity in patients with IKK-γ/NEMO mutations. In: Journal of Clinical Investigation. 2002 ; Vol. 109, No. 11. pp. 1501-1509.
@article{1337faa63a674765a499263fba314eaa,
title = "Deficient natural killer cell cytotoxicity in patients with IKK-γ/NEMO mutations",
abstract = "NF-κB essential modifier (NEMO), also known as IKK-κ, is a member of the I-γB kinase complex responsible for phosphorylating I-κB, allowing the release and activation of NF-κB. Boys with an expressed NEMO mutation have an X-linked syndrome characterized by hypohidrotic ectodermal dysplasia with immune deficiency (HED-ID). The immunophenotype resulting from NEMO mutation is highly variable, with deficits in both T and B cell responses. We evaluated three patients with NEMO mutations (L153R, Q403X, and C417R) and HED-ID who had evidence of defective CD40 signaling. All three patients had normal percentages of peripheral blood NK cells, but impaired NK cell cytotoxic activity. This was not due to a generalized defect in cytotoxicity because antibody-dependent cellular cytotoxicity was intact. This abnormality was partially reversed by in vitro addition of IL-2, which was also able to induce NF-κB activation. In one patient with recurrent cytomegalovirus infections, administration of IL-2 partially corrected the NK cell killing deficit. These data suggest that NEMO participates in signaling pathways leading to NK cell cytotoxicity and that IL-2 can activate NF-κB and partially overcome the NK cell defect in patients with NEMO mutations.",
author = "Orange, {Jordan S.} and Brodeur, {Scott R.} and Ashish Jain and Bonilla, {Francisco A.} and Schneider, {Lynda C.} and Roberto Kretschmer and Samuel Nurko and Rasmussen, {Wendy L.} and K{\"o}hler, {Julia R.} and Gellis, {Stephen E.} and Betsy Ferguson and Strominger, {Jack L.} and Zonana, {Jonathan (Jon)} and Narayanaswamy Ramesh and Ballas, {Zuhair K.} and Geha, {Raif S.}",
year = "2002",
doi = "10.1172/JCI200214858",
language = "English (US)",
volume = "109",
pages = "1501--1509",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "11",

}

TY - JOUR

T1 - Deficient natural killer cell cytotoxicity in patients with IKK-γ/NEMO mutations

AU - Orange, Jordan S.

AU - Brodeur, Scott R.

AU - Jain, Ashish

AU - Bonilla, Francisco A.

AU - Schneider, Lynda C.

AU - Kretschmer, Roberto

AU - Nurko, Samuel

AU - Rasmussen, Wendy L.

AU - Köhler, Julia R.

AU - Gellis, Stephen E.

AU - Ferguson, Betsy

AU - Strominger, Jack L.

AU - Zonana, Jonathan (Jon)

AU - Ramesh, Narayanaswamy

AU - Ballas, Zuhair K.

AU - Geha, Raif S.

PY - 2002

Y1 - 2002

N2 - NF-κB essential modifier (NEMO), also known as IKK-κ, is a member of the I-γB kinase complex responsible for phosphorylating I-κB, allowing the release and activation of NF-κB. Boys with an expressed NEMO mutation have an X-linked syndrome characterized by hypohidrotic ectodermal dysplasia with immune deficiency (HED-ID). The immunophenotype resulting from NEMO mutation is highly variable, with deficits in both T and B cell responses. We evaluated three patients with NEMO mutations (L153R, Q403X, and C417R) and HED-ID who had evidence of defective CD40 signaling. All three patients had normal percentages of peripheral blood NK cells, but impaired NK cell cytotoxic activity. This was not due to a generalized defect in cytotoxicity because antibody-dependent cellular cytotoxicity was intact. This abnormality was partially reversed by in vitro addition of IL-2, which was also able to induce NF-κB activation. In one patient with recurrent cytomegalovirus infections, administration of IL-2 partially corrected the NK cell killing deficit. These data suggest that NEMO participates in signaling pathways leading to NK cell cytotoxicity and that IL-2 can activate NF-κB and partially overcome the NK cell defect in patients with NEMO mutations.

AB - NF-κB essential modifier (NEMO), also known as IKK-κ, is a member of the I-γB kinase complex responsible for phosphorylating I-κB, allowing the release and activation of NF-κB. Boys with an expressed NEMO mutation have an X-linked syndrome characterized by hypohidrotic ectodermal dysplasia with immune deficiency (HED-ID). The immunophenotype resulting from NEMO mutation is highly variable, with deficits in both T and B cell responses. We evaluated three patients with NEMO mutations (L153R, Q403X, and C417R) and HED-ID who had evidence of defective CD40 signaling. All three patients had normal percentages of peripheral blood NK cells, but impaired NK cell cytotoxic activity. This was not due to a generalized defect in cytotoxicity because antibody-dependent cellular cytotoxicity was intact. This abnormality was partially reversed by in vitro addition of IL-2, which was also able to induce NF-κB activation. In one patient with recurrent cytomegalovirus infections, administration of IL-2 partially corrected the NK cell killing deficit. These data suggest that NEMO participates in signaling pathways leading to NK cell cytotoxicity and that IL-2 can activate NF-κB and partially overcome the NK cell defect in patients with NEMO mutations.

UR - http://www.scopus.com/inward/record.url?scp=0036259559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036259559&partnerID=8YFLogxK

U2 - 10.1172/JCI200214858

DO - 10.1172/JCI200214858

M3 - Article

VL - 109

SP - 1501

EP - 1509

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 11

ER -